AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Myriad Genetics Inc
XNAS · usd
SIC 2835 · IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
FIGI BBG001S86FS9
5.82▲ 0.06 (1.04%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
5.76
Day's Range
5.60 – 5.86
52-Week Range
2.74 – 8.50
Volume
2.1M
Avg Volume
2.9M
Share Statistics
Shares Outstanding
Employees
2,700
Exchange
XNAS
Listed
1995-10-06
Share count as of July 28, 2026

Myriad Genetics Inc (MYGN) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Myriad Genetics Inc (MYGN)
What is Myriad Genetics Inc's Market Cap?
Myriad Genetics Inc's Market Cap is $556.7M, based on as-reported figures from SEC (XBRL) filings.
What is Myriad Genetics Inc's Enterprise Value?
Myriad Genetics Inc's Enterprise Value is $562.2M, based on as-reported figures from SEC (XBRL) filings.
What is Myriad Genetics Inc's Price / Sales?
Myriad Genetics Inc's Price / Sales is 0.7×, based on as-reported figures from SEC (XBRL) filings.
What is Myriad Genetics Inc's EV / Revenue?
Myriad Genetics Inc's EV / Revenue is 0.7×, based on as-reported figures from SEC (XBRL) filings.
What is Myriad Genetics Inc's EV / EBITDA?
Myriad Genetics Inc's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Myriad Genetics Inc's Revenue (TTM)?
Myriad Genetics Inc's Revenue (TTM) is $806.6M, based on as-reported figures from SEC (XBRL) filings.
What is Myriad Genetics Inc's Net Income (TTM)?
Myriad Genetics Inc's Net Income (TTM) is -$112.6M, based on as-reported figures from SEC (XBRL) filings.
What is Myriad Genetics Inc's EBITDA?
Myriad Genetics Inc's EBITDA is -$48.4M, based on as-reported figures from SEC (XBRL) filings.
What is Myriad Genetics Inc's Diluted EPS (TTM)?
Myriad Genetics Inc's Diluted EPS (TTM) is -1.18, based on as-reported figures from SEC (XBRL) filings.
What is Myriad Genetics Inc's EBITDA Margin?
Myriad Genetics Inc's EBITDA Margin is -6.0%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · MYGNAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenue
YoY growth-10.5%+2.3%-0.4%-3.6%
Cost of revenue
Gross profit
% of revenue66.6%68.7%70.0%69.9%
Costs and expenses:
Research and development expense
Sales and marketing expense
General and administrative expense
Goodwill and long-lived asset impairment charges
Total operating expenses
% of revenue87.0%84.0%72.7%81.2%
Operating loss
% of revenue-20.4%-15.3%-2.7%-11.3%
Other income (expense):
Interest income
Interest expense
Other
Total other expense, net
Loss before income tax
Income tax expense (benefit)
Net loss
% of revenue-22.7%-17.0%-3.8%-13.3%
Basic (dollars per share)
Diluted (dollars per share)